Synergistic activity of letrozole and sorafenib on breast cancer cells

Breast Cancer Research and Treatment

Volumn 124, Issue 1, 2010, Pages 79-88

  Bonelli, Mara A ^a   Fumarola, Claudia ^a   Alfieri, Roberta R ^a   La Monica, Silvia ^a   Cavazzoni, Andrea ^a   Galetti, Maricla ^a   Gatti, Rita ^a   Belletti, Silvana ^a   Harris, Adrian L ^b   Fox, Stephen B ^c   Evans, Dean B ^d   Dowsett, Mitch ^e   Martin, Lesley Ann ^f   Bottini, Alberto ^g   Generali, Daniele ^g,h   Petronini, Pier Giorgio ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d NOVARTIS PHARMA AG   (Switzerland)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g Unità di Patologia Mammaria Breast Cancer Unit   (Italy)

^h Centro di Medicina Molecolare   (Italy)

Author keywords

Breast cancer; Letrozole; mTORC1; Sorafenib

Indexed keywords

APOPTOSIS INDUCING FACTOR; CASPASE 7; CASPASE 9; CYCLIN D1; CYTOCHROME C; ESTROGEN; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; RAF PROTEIN; SORAFENIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; ESTROGEN SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SECRETION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; AROMATASE; AROMATASE INHIBITORS; BENZENESULFONATES; BREAST NEOPLASMS; CASPASE 7; CASPASE 9; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESTRADIOL; FEMALE; HUMANS; NITRILES; PHOSPHOPROTEINS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; PYRIDINES; RETINOBLASTOMA PROTEIN; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TESTOSTERONE; TIME FACTORS; TRANSFECTION; TRIAZOLES;

EID: 77957702355     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0714-5     Document Type: Article

References (47)

1. CK Osborne J Shou S Massarweh R Schiff 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer Clin Cancer Res 11 865s 870s 1:CAS:528: DC%2BD2MXislWgu7k%3D 15701879
2. L Bjornstrom M Sjoberg 2005 Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes Mol Endocrinol 19 833 842 10.1210/me.2004-0486 15695368
3. A Migliaccio M Di Domenico G Castoria, et al. 1996 Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells EMBO J 15 1292 1300 1:CAS:528:DyaK28XitFWjtLo%3D 8635462
4. P Le Goff MM Montano DJ Schodin BS Katzenellenbogen 1994 Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity J Biol Chem 269 4458 4466 8308015
5. S Kato H Endoh Y Masuhiro, et al. 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase Science 270 1491 1494 1:CAS:528:DyaK2MXps12hs7o%3D 10.1126/science.270.5241.1491 7491495
6. IE Smith M Dowsett 2003 Aromatase inhibitors in breast cancer N Engl J Med 348 2431 2442 1:CAS:528:DC%2BD3sXksFKguro%3D 10.1056/NEJMra023246 12802030
7. BP Haynes M Dowsett WR Miller JM Dixon AS Bhatnagar 2003 The pharmacology of letrozole J Steroid Biochem Mol Biol 87 35 45 1:CAS:528:DC%2BD3sXptVemtrw%3D 10.1016/S0960-0760(03)00384-4 14630089
8. AS Bhatnagar 2006 Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting Breast 15 Suppl 1 S3 S13 10.1016/j.breast.2006.01.001 16500235
9. R Schiff SA Massarweh J Shou L Bharwani SK Mohsin CK Osborne 2004 Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance Clin Cancer Res 10 331S 336S 1:CAS:528:DC%2BD2cXkvF2ksw%3D%3D 10.1158/1078-0432.CCR-031212 14734488
10. SR Johnston LA Martin A Leary J Head M Dowsett 2007 Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer J Steroid Biochem Mol Biol 106 180 186 1:CAS:528: DC%2BD2sXhtVWitbjI 10.1016/j.jsbmb.2007.05.019 17624764
11. J Gligorov D Azria M Namer D Khayat JP Spano 2007 Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives Crit Rev Oncol Hematol 64 115 128 10.1016/j.critrevonc.2007.06.010 17702596
12. D Generali FM Buffa A Berruti, et al. 2009 Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer J Clin Oncol 27 227 234 10.1200/JCO.2007.13.7083 19064988
13. RC Kane AT Farrell H Saber, et al. 2006 Sorafenib for the treatment of advanced renal cell carcinoma Clin Cancer Res 12 7271 7278 1:CAS:528: DC%2BD28XhtlCrtr7P 10.1158/1078-0432.CCR-06-1249 17189398
14. RC Kane AT Farrell R Madabushi, et al. 2009 Sorafenib for the treatment of unresectable hepatocellular carcinoma Oncologist 14 95 100 1:CAS:528:DC%2BD1MXjt1CltL4%3D 10.1634/theoncologist.2008-0185 19144678
15. SM Wilhelm C Carter L Tang, et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 7109 1:CAS:528:DC%2BD2cXotFalsbk%3D 10.1158/0008-5472.CAN-04-1443 15466206
16. I Plaza-Menacho L Mologni E Sala, et al. 2007 Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting J Biol Chem 282 29230 29240 1:CAS:528:DC%2BD2sXhtV2ntbvF 10.1074/jbc.M703461200 17664273
17. A Sharma NR Trivedi MA Zimmerman DA Tuveson CD Smith GP Robertson 2005 Mutant V599 EB-Raf regulates growth and vascular development of malignant melanoma tumors Cancer Res 65 2412 2421 1:CAS:528:DC%2BD2MXisFGns7Y%3D 10.1158/0008-5472.CAN-04-2423 15781657
18. L Liu Y Cao C Chen, et al. 2006 Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 11851 11858 1:CAS:528: DC%2BD28Xhtlagu73F 10.1158/0008-5472.CAN-06-1377 17178882
19. DJ Panka W Wang MB Atkins JW Mier 2006 The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells Cancer Res 66 1611 1619 1:CAS:528:DC%2BD28XpsVenug%3D%3D 10.1158/0008-5472.CAN-05-0808 16452220
20. A Huether M Hopfner V Baradari D Schuppan H Scherubl 2007 Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma Biochem Pharmacol 73 1308 1317 1:CAS:528:DC%2BD2sXjsVGitLw%3D 10.1016/j.bcp.2006.12.031 17266941
21. M Rahmani EM Davis C Bauer P Dent S Grant 2005 Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation J Biol Chem 280 35217 35227 1:CAS:528:DC%2BD2MXhtFWmtbnP 10.1074/jbc.M506551200 16109713
22. Q Ding L Huo JY Yang, et al. 2008 Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer Cancer Res 68 6109 6117 1:CAS:528: DC%2BD1cXpt1Sqtbs%3D 10.1158/0008-5472.CAN-08-0579 18676833
23. Huynh H, Ngo VC, Koong HN et al (2009) Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med. doi: 10.1111/j.1582-4934.2009.00692.x
24. SM Kumar H Yu R Edwards, et al. 2007 Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma Cancer Res 67 3177 3184 1:CAS:528:DC%2BD2sXksVGlu7k%3D 10.1158/0008-5472.CAN-06-3312 17409425
25. VM Macaulay JE Nicholls J Gledhill MG Rowlands M Dowsett A Ashworth 1994 Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells Br J Cancer 69 77 83 1:CAS:528: DyaK2cXisVWns7g%3D 8286214
26. S Banerjee M Zvelebil P Furet, et al. 2009 The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase Cancer Res 69 4716 4723 1:CAS:528:DC%2BD1MXmsFGlurs%3D 10.1158/0008-5472.CAN-08-4711 19435899
27. A Cavazzoni PG Petronini M Galetti, et al. 2004 Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line Oncogene 23 8439 8446 1:CAS:528:DC%2BD2cXpt1OmsLg%3D 10.1038/sj.onc.1207847 15361849
28. C Fumarola S La Monica RR Alfieri E Borra GG Guidotti 2005 Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis Cell Death Differ 12 1344 1357 1:CAS:528: DC%2BD2MXpvFCjur4%3D 10.1038/sj.cdd.4401660 15905878
29. M Goldoni C Johansson 2007 A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model Toxicol In Vitro 21 759 769 1:CAS:528: DC%2BD2sXksFens7c%3D 17420112
30. S La Monica M Galetti RR Alfieri, et al. 2009 Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines Biochem Pharmacol 78 460 468 1:CAS:528:DC%2BD1MXotFOlt7s%3D 10.1016/j.bcp.2009.04.033 19427302
31. R Aesoy BC Sanchez JH Norum R Lewensohn K Viktorsson B Linderholm 2008 An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells Mol Cancer Res 6 1630 1638 1:CAS:528:DC%2BD1cXht1Cmsb%2FO 10.1158/1541-7786.MCR-07-2172 18922978
32. C Lathia J Lettieri F Cihon M Gallentine M Radtke P Sundaresan 2006 Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics Cancer Chemother Pharmacol 57 685 692 1:CAS:528: DC%2BD28Xjs1KktLk%3D 10.1007/s00280-005-0068-6 16133532
33. D Strumberg JW Clark A Awada, et al. 2007 Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors Oncologist 12 426 437 1:CAS:528:DC%2BD2sXmtlSitrs%3D 10.1634/theoncologist.12-4-426 17470685
34. R Gatti S Belletti G Orlandini O Bussolati V Dall'Asta GC Gazzola 1998 Comparison of annexin V and calcein-AM as early vital markers of apoptosis in adherent cells by confocal laser microscopy J Histochem Cytochem 46 895 900 1:CAS:528:DyaK1cXltVOlt7s%3D 9671440
35. S Kagawa J Gu T Honda, et al. 2001 Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear fragmentation but not cell death Clin Cancer Res 7 1474 1480 1:CAS:528:DC%2BD3MXktlelsLo%3D 11350920
36. FJ Oliver G de la Rubia V Rolli MC Ruiz-Ruiz G de Murcia JM Murcia 1998 Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant J Biol Chem 273 33533 33539 1:CAS:528: DyaK1MXmvA%3D%3D 10.1074/jbc.273.50.33533 9837934
37. KE O'Reilly F Rojo QB She, et al. 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 1500 1508 10.1158/0008-5472.CAN-05-2925 16452206
38. A Belosay AM Brodie VC Njar 2006 Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells Cancer Res 66 11485 11493 1:CAS:528:DC%2BD28Xht1KnsLrI 10.1158/0008-5472.CAN- 06-2168 17145897
39. S Wilhelm DS Chien 2002 BAY 43-9006: preclinical data Curr Pharm Des 8 2255 2257 1:CAS:528:DC%2BD38XnvVGntrs%3D 10.2174/1381612023393026 12369853
40. C Yu LM Bruzek XW Meng, et al. 2005 The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006 Oncogene 24 6861 6869 1:CAS:528:DC%2BD2MXhtFamsLbE 10.1038/sj.onc.1208841 16007148
41. MA Tran CD Smith M Kester GP Robertson 2008 Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development Clin Cancer Res 14 3571 3581 1:CAS:528:DC%2BD1cXmslygt70%3D 10.1158/1078-0432.CCR-07-4881 18519791
42. KR Molhoek DL Brautigan CL Slingluff Jr 2005 Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin J Transl Med 3 39 10.1186/1479-5876-3-39 16255777
43. A Carracedo L Ma J Teruya-Feldstein, et al. 2008 Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J Clin Invest 118 3065 3074 1:CAS:528:DC%2BD1cXhtV2isb3P 18725988
44. DG DeNardo VL Cuba H Kim K Wu AV Lee PH Brown 2007 Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth Mol Cell Endocrinol 277 13 25 1:CAS:528:DC%2BD2sXhtFelsLnJ 10.1016/j.mce.2007.07.006 17825481
45. Y Shi A Sharma H Wu A Lichtenstein J Gera 2005 Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway J Biol Chem 280 10964 10973 1:CAS:528:DC%2BD2MXisVOqtbk%3D 10.1074/jbc. M407874200 15634685
46. J Zhou J Wulfkuhle H Zhang, et al. 2007 Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance Proc Natl Acad Sci USA 104 16158 16163 1:CAS:528:DC%2BD2sXhtF2hu7fI 10.1073/pnas.0702596104 17911267
47. RI Nicholson RA McClelland JF Robertson JM Gee 1999 Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer Endocr Relat Cancer 6 373 387 1:CAS:528:DyaK1MXmsVOmt7k%3D 10.1677/erc.0.0060373 10516852